東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Synthetic Biology Approaches to Impr...

Cho, Jang Hwan.

FindBook

Google Book

Amazon

博客來

Synthetic Biology Approaches to Improve Cell-Based Cancer Immunotherapy.

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Synthetic Biology Approaches to Improve Cell-Based Cancer Immunotherapy./
作者:	Cho, Jang Hwan.
出版者:	Ann Arbor : ProQuest Dissertations & Theses, : 2019,
面頁冊數:	184 p.
附註:	Source: Dissertations Abstracts International, Volume: 81-03, Section: B.
Contained By:	Dissertations Abstracts International81-03B.
標題:	Biomedical engineering. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13857335
ISBN:	9781085619134

Synthetic Biology Approaches to Improve Cell-Based Cancer Immunotherapy.
Cho, Jang Hwan.

Synthetic Biology Approaches to Improve Cell-Based Cancer Immunotherapy. - Ann Arbor : ProQuest Dissertations & Theses, 2019 - 184 p.

Source: Dissertations Abstracts International, Volume: 81-03, Section: B.

Thesis (Ph.D.)--Boston University, 2019.

This item must not be sold to any third party vendors.

Adoptive T cell immunotherapy is a promising anti-cancer therapy that has the potential to become the ultimate therapeutic agents to treat a variety of diseases. Recently, chimeric antigen receptor (CAR) expressing T cells has demonstrated to be a very effective approach to treat B cell cancer patients. Despite optimistic results, there are several improvements that need to be made to enhance the safety and efficacy of current CAR T cell therapy. Fortunately, different synthetic biology tools can be implemented to overcome many of the current deficiencies of CAR T cell therapy. Here, we develop anti-Axl CAR and synNotch receptors to target Axl which is a tyrosine kinase receptor that is commonly overexpressed in many cancers and considered as one of important cancer therapeutic targets. Next, we develop a split, universal, and programmable (SUPRA) CAR system that can be used to switch targets without re-engineering T cells, fine-tune T cell activation level, and sense and logically respond to multiple antigens. These multiple features are useful in mitigating tumor relapse, limiting CAR-T induced toxicities, and enhancing tumor specificity. Orthogonal SUPRA CARs are also used to control different cell types and signaling domains, enabling diverse immune responses from SUPRA CAR T cells. Lastly, we demonstrate that SUPRA CAR can redirect the activity of both innate and adaptive immune cell types. We also expand the logic capabilities of SUPRA CAR T cells by integrating three inputs in a single immune cell. We also show intercellular logic gate by engineering immune cell-cell interaction. We further demonstrate controlling endogenous immune cell polarization using SUPRA CAR T cells. These wide-ranges of SUPRA CAR applications imply its versatility as a platform for engineering cell-cell interactions with advanced logic functions to enhance efficacy and safety of cell-based cancer immunotherapy.

ISBN: 9781085619134Subjects--Topical Terms:

535387
Biomedical engineering.
Subjects--Index Terms:

Anti-cancer therapy

Synthetic Biology Approaches to Improve Cell-Based Cancer Immunotherapy.
LDR:03266nmm a2200433 4500 001 2272458
005 20201105110059.5
008 220629s2019 ||||||||||||||||| ||eng d
020 $a 9781085619134
035 $a (MiAaPQ)AAI13857335
035 $a AAI13857335
040 $a MiAaPQ $c MiAaPQ
100 1 $a Cho, Jang Hwan. $3 3174122
245 1 0 $a Synthetic Biology Approaches to Improve Cell-Based Cancer Immunotherapy.
260 1 $a Ann Arbor : $b ProQuest Dissertations & Theses, $c 2019
300 $a 184 p.
500 $a Source: Dissertations Abstracts International, Volume: 81-03, Section: B.
500 $a Advisor: Wong, Wilson W.;Collins, James J.
502 $a Thesis (Ph.D.)--Boston University, 2019.
506 $a This item must not be sold to any third party vendors.
506 $a This item must not be added to any third party search indexes.
520 $a Adoptive T cell immunotherapy is a promising anti-cancer therapy that has the potential to become the ultimate therapeutic agents to treat a variety of diseases. Recently, chimeric antigen receptor (CAR) expressing T cells has demonstrated to be a very effective approach to treat B cell cancer patients. Despite optimistic results, there are several improvements that need to be made to enhance the safety and efficacy of current CAR T cell therapy. Fortunately, different synthetic biology tools can be implemented to overcome many of the current deficiencies of CAR T cell therapy. Here, we develop anti-Axl CAR and synNotch receptors to target Axl which is a tyrosine kinase receptor that is commonly overexpressed in many cancers and considered as one of important cancer therapeutic targets. Next, we develop a split, universal, and programmable (SUPRA) CAR system that can be used to switch targets without re-engineering T cells, fine-tune T cell activation level, and sense and logically respond to multiple antigens. These multiple features are useful in mitigating tumor relapse, limiting CAR-T induced toxicities, and enhancing tumor specificity. Orthogonal SUPRA CARs are also used to control different cell types and signaling domains, enabling diverse immune responses from SUPRA CAR T cells. Lastly, we demonstrate that SUPRA CAR can redirect the activity of both innate and adaptive immune cell types. We also expand the logic capabilities of SUPRA CAR T cells by integrating three inputs in a single immune cell. We also show intercellular logic gate by engineering immune cell-cell interaction. We further demonstrate controlling endogenous immune cell polarization using SUPRA CAR T cells. These wide-ranges of SUPRA CAR applications imply its versatility as a platform for engineering cell-cell interactions with advanced logic functions to enhance efficacy and safety of cell-based cancer immunotherapy.
590 $a School code: 0017.
650 4 $a Biomedical engineering. $3 535387
650 4 $a Physiology. $3 518431
650 4 $a Medicine. $3 641104
650 4 $a Epidemiology. $3 568544
650 4 $a Public health. $3 534748
650 4 $a Oncology. $3 751006
650 4 $a Health sciences. $3 3168359
650 4 $a Pathology. $3 643180
653 $a Anti-cancer therapy
653 $a B cell cancer patients
653 $a Chimeric antigen receptor
653 $a Immune cell types
690 $a 0541
690 $a 0573
690 $a 0571
690 $a 0566
690 $a 0992
690 $a 0564
690 $a 0766
690 $a 0719
710 2 $a Boston University. $b Biomedical Engineering ENG. $3 3193140
773 0 $t Dissertations Abstracts International $g 81-03B.
790 $a 0017
791 $a Ph.D.
792 $a 2019
793 $a English
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=13857335